The 786-O human kidney cancer cell line was chosen for our proof of concept tumor endothelial cell (EC) expression engineering because these cells form hypervascular tumors in immunodeficient hosts due to constitutive, high level expression of hypoxia-inducible factor-2, and its downstream target vascular endothelial growth factor [23], [24]. Here, VEGFA is linked to neoplasm.